{"disease":{"id":"treatment-of-adult-patients-with-hormone-receptor-hr-positive-human-epidermal-growth-factor-receptor-2-her2-negative-advanced-or-metastatic-breast-cancer-in-combination-with-an-aromatase-inhibitor-as-initial-endocrine-based-therapy","name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"palbociclib","guideline_body":"FDA label","recommendation":"Palbociclib is indicated for use in combination with an aromatase inhibitor as initial endocrine-based therapy.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"palbociclib","guideline_body":"FDA label","recommendation":"Palbociclib is indicated for use in combination with fulvestrant in patients with disease progression following endocrine therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"palbociclib","guideline_body":"FDA label","recommendation":"Palbociclib is indicated for use in combination with inavolisib and fulvestrant for the treatment of endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}